18,927 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 18,927 shares of the company’s stock, valued at approximately $3,190,000.

A number of other institutional investors have also recently bought and sold shares of NBIX. Capital Square LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $225,000. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $895,000. Globeflex Capital L P acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $4,780,000. Bank of Nova Scotia acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $981,000. Finally, Daiichi Life Insurance Co. Ltd. bought a new position in Neurocrine Biosciences during the 2nd quarter worth $2,484,000. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on NBIX shares. Canaccord Genuity Group lifted their price objective on Neurocrine Biosciences from $200.00 to $210.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research cut Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. Citigroup boosted their price target on Neurocrine Biosciences from $246.00 to $249.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Morgan Stanley cut their price objective on shares of Neurocrine Biosciences from $196.00 to $182.00 and set an “equal weight” rating for the company in a research report on Thursday, August 13th. Finally, Truist Financial raised their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $200.86.

Insiders Place Their Bets

In related news, insider Darin Lippoldt sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the sale, the insider directly owned 54,729 shares of the company’s stock, valued at $9,829,328.40. This trade represents a 15.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 4,367 shares of Neurocrine Biosciences stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $181.02, for a total value of $790,514.34. Following the completion of the transaction, the insider owned 16,225 shares in the company, valued at approximately $2,937,049.50. This represents a 21.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 116,636 shares of company stock valued at $19,349,078. 4.60% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $153.37 on Wednesday. The business has a fifty day moving average price of $166.95 and a two-hundred day moving average price of $149.17. The stock has a market capitalization of $15.59 billion, a PE ratio of 22.49, a PEG ratio of 0.72 and a beta of 0.39. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The company had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. During the same quarter last year, the company posted $1.65 EPS. The company’s revenue for the quarter was up 39.5% compared to the same quarter last year. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.